Show simple item record

dc.contributor.authorVenkatesulu, B.
dc.contributor.authorLiauw, S. L.
dc.contributor.authorJoshi, M.
dc.contributor.authorBaumann, B. C.
dc.contributor.authorYoo, R.
dc.contributor.authorRoupret, M.
dc.contributor.authorChoudhury, Ananya
dc.contributor.authorEfstathiou, J. A.
dc.contributor.authorMurthy, V.
dc.contributor.authorSargos, P.
dc.contributor.authorSolanki, A. A.
dc.date.accessioned2023-01-24T10:32:12Z
dc.date.available2023-01-24T10:32:12Z
dc.date.issued2023en
dc.identifier.citationVenkatesulu B, Liauw SL, Joshi M, Baumann BC, Yoo R, Roupret M, et al. Multidisciplinary Management and Radiotherapy Recommendations for Clinically and Pathologically Node-positive Bladder Cancer. Seminars in radiation oncology. 2023 Jan;33(1):35-50. PubMed PMID: 36517192. Epub 2022/12/15. eng.en
dc.identifier.pmid36517192en
dc.identifier.doi10.1016/j.semradonc.2022.10.005en
dc.identifier.urihttp://hdl.handle.net/10541/625915
dc.description.abstractThere are limited data regarding the optimal management of patients with pelvic node-positive, but non-metastatic, bladder cancer. Increasing data demonstrate that this is a distinct clinical entity with outcomes bridging between bladder-confined muscle-invasive bladder cancer and metastatic advanced bladder cancer. Guidelines and staging systems have formalized the need to incorporate the unique considerations of management of pelvic node-positive bladder cancer. However, there remains an absence of a definite standard of care. Treatment options include systemic therapy alone, neoadjuvant chemotherapy followed by radical cystectomy, or bladder-preserving trimodality therapy. Furthermore, ongoing studies aim to determine the benefit of incorporating immunotherapy into these treatment paradigms. In this review article, we will discuss the key considerations for management of patients with pelvic node-positive bladder cancer.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.semradonc.2022.10.005en
dc.titleMultidisciplinary management and radiotherapy recommendations for clinically and pathologically node-positive bladder canceren
dc.typeArticleen
dc.contributor.departmentDepartment of Radiation Oncology, Cardinal Bernardin Cancer Center, Loyola University Chicago, Stritch School of Medicine, Maywood,en
dc.identifier.journalSeminars in Radiation Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record